New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
|Articles|October 8, 2014
- NSCLC (Issue 4)
- Volume 4
- Issue 1
The Importance of Biomarkers for Lung Cancer
Author(s)Fred R. Hirsch, MD, PhD
Fred R. Hirsch, MD, PhD, Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the importance of biomarkers for lung cancer.
Advertisement
Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the importance of biomarkers for lung cancer.
Articles in this issue
about 12 years ago
The Implementation of Personalized Medicine for Lung Cancer Patientsabout 12 years ago
The Benefit of Treating Lung Cancer with Immunotherapyabout 12 years ago
The Cancer Genome Atlas Plays Role in Future Therapies for NSCLCabout 12 years ago
In Practice: Systemic Treatment for Metastatic NSCLCabout 12 years ago
Clinical Trial Profile: The OAK Studyabout 12 years ago
Optimizing of Therapeutic Sequencing Being Studied in NSCLCAdvertisement
Related to this article
ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab and pumitamig plus docetaxel showed activity in PD-L1–high and post-chemoimmunotherapy disease.
ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials.
Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.
Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5